What is the main risk associated with untreated APS regarding venous thromboembolism during pregnancy?

What is the main risk associated with untreated APS regarding venous thromboembolism during pregnancy?

• A. 5-10% risk
• B. 5-12% risk
• C. 10-15% risk
• D. 15-20% risk

Answer: (B)

The main risk associated with untreated Antiphospholipid Syndrome (APS) during pregnancy for developing venous thromboembolism is recognized to be in the range of 5-12%. APS is a significant risk factor for thrombosis, particularly during the physiological changes of pregnancy, which include increased coagulability and changes in blood flow dynamics. Without appropriate management, pregnant individuals with APS face an elevated risk of developing blood clots. It is critical for healthcare providers to be aware of this risk range to appropriately monitor and manage patients with APS during pregnancy, considering the potential complications that can arise from venous thromboembolism, such as deep vein thrombosis or pulmonary embolism. The other risk ranges listed exceed this established risk percentage associated with untreated APS in pregnancy.

The main risk associated with untreated Antiphospholipid Syndrome (APS) during pregnancy for developing venous thromboembolism is recognized to be in the range of 5-12%. APS is a significant risk factor for thrombosis, particularly during the physiological changes of pregnancy, which include increased coagulability and changes in blood flow dynamics. Without appropriate management, pregnant individuals with APS face an elevated risk of developing blood clots.

It is critical for healthcare providers to be aware of this risk range to appropriately monitor and manage patients with APS during pregnancy, considering the potential complications that can arise from venous thromboembolism, such as deep vein thrombosis or pulmonary embolism. The other risk ranges listed exceed this established risk percentage associated with untreated APS in pregnancy.